SCHEMBL4227434

SCHEMBL4227434

O=C(/C=C/c1cnc(NC2CCN(C(=O)c3ccccc3Cl)CC2)c(Cl)c1)NOC1CCCCO1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 3/20 0.47
EPHX2 P34913 1/20 0.40
EGLN1 Q9GZT9 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
SYK P43405 1/20 0.37
BTK Q06187 4/20 0.36
RAB9A P51151 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
GPR6 P46095 1/20 0.36
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTR2B P41595 1/20 0.35
MAPK14 Q16539 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SFRP1 Q8N474 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227443 1.00 PAK1 (0.47) PAK1EPHX2EGLN1TDP1SYK
SCHEMBL4227796 0.96 PAK1 (0.42) PAK1EPHX2EGLN1TDP1SYK
SCHEMBL4227790 0.96 PAK1 (0.42) PAK1EPHX2EGLN1TDP1SYK
SCHEMBL4228042 0.92 NPY2R (0.41) PAK1CCNA2CDK2CCNA1CDK5
SCHEMBL4228045 0.92 NPY2R (0.41) PAK1CCNA2CDK2CCNA1CDK5
SCHEMBL4220540 0.89 PAK1 (0.45) PAK1EPHX2EGLN1GPR6
SCHEMBL4220533 0.89 PAK1 (0.45) PAK1EPHX2EGLN1GPR6
SCHEMBL4229832 0.88 L3MBTL1 (0.40) PAK1EPHX2EGLN1SYKCYP2C19
SCHEMBL4229837 0.88 L3MBTL1 (0.40) PAK1EPHX2EGLN1SYKCYP2C19
SCHEMBL4222080 0.88 BTK (0.40) PAK1SYKBTKCYP2C9NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
EP-1776357-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) Astellas Pharma Inc. (JP) 2007-04-25 EP disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed
WO-2006016680-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) ASTELLAS PHARMA INC. (JP) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 PAK1 2009/4885EPHX2 3290/4885EGLN1 533/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 PAK1 1257/4885EPHX2 3317/4885EGLN1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.